Compare ASMB & LXFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASMB | LXFR |
|---|---|---|
| Founded | 2005 | 1898 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.0M | 421.4M |
| IPO Year | 2010 | 2002 |
| Metric | ASMB | LXFR |
|---|---|---|
| Price | $27.46 | $12.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $43.40 | N/A |
| AVG Volume (30 Days) | 91.8K | ★ 123.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.10% |
| EPS Growth | ★ 50.00 | N/A |
| EPS | N/A | ★ 0.28 |
| Revenue | N/A | ★ $384,600,000.00 |
| Revenue This Year | $33.33 | N/A |
| Revenue Next Year | N/A | $5.01 |
| P/E Ratio | ★ N/A | $45.29 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.76 | $9.41 |
| 52 Week High | $39.71 | $16.03 |
| Indicator | ASMB | LXFR |
|---|---|---|
| Relative Strength Index (RSI) | 46.25 | 28.67 |
| Support Level | $26.50 | $12.29 |
| Resistance Level | $31.27 | $13.62 |
| Average True Range (ATR) | 1.79 | 0.60 |
| MACD | 0.17 | -0.34 |
| Stochastic Oscillator | 40.41 | 2.39 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.